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Introduction
Case Presentation 
What is Kratom• Kratom (Mitragyna speciosa) is an herb native to Southeast Asia with 
opioid and stimulant-like properties that is commonly used to achieve 
a legal recreational high. 
• Kratom purchase and consumption is legal in most U.S. states.
• Cases of acute toxicity and withdrawal have been increasing over the 
past decade. 
Legality of Kratom
• Kratom has a long history of abuse in SE Asia and is a controlled 
substance in this region.
• The DEA is aware of the dangers of Kratom, however it is not 
currently a scheduled substance.
• As of 2020, there are no federal laws prohibiting Kratom use. 
Purchase and consumption is legal in most states.
Increasing use/abuse in U.S.
• Kratom use in the U.S. has been steadily increasing since 2010 
which has caused in increase in the amount of cases of acute 
toxicity and withdrawal. 
Figure left: Annual number of Kratom exposures reported to poison control centers in the 
the U.S. from 2011 through 2017
Kratom Withdrawal 
Increasing use/abuse in U.S.
• Withdrawal symptoms are common after discontinuing use following weeks to 
months of daily use.
• Kratom withdrawal begins approximately 12 hours after last use.
• Duration of kratom withdrawal is similar to that opioid withdrawal. 
Symptoms of Kratom withdrawal 
Treatment
• There are no concrete guidelines on management of Kratom withdrawal, 
however, multiple case reports have described successful treatment with 
symptom-triggered clonidine & scheduled hydroxyzine during acute phase.
• Case reports have also described success with transitioning patients onto long 
term buprenorphine-naloxone maintenance.
Pre-hospital course
• Well adjusted 38 y.o. male presented with respiratory arrest requiring 
intubation by EMS in the field.
• Found to have pinpoint pupils and bradypnea that was minimally 
responsive to naloxone.
ICU course
• Transferred to ICU and quickly extubated.
• 12 hours after arrival the patient became tachycardiac, tachypneic, 
and developed a new tremor along with new visual hallucinations.
• Patient was reintubated due to progression of symptoms.
• Was restarted on his home dose of tramadol due to fear of withdrawal, 
symptoms persisted. 
• A Fentanyl drip provided minor improvement in his tremors and 
hallucinations.
History 
• Leaves were historically chewed by laborers in SE Asia to combat fatigue and to 
help treat aches and pains.
Current uses
• Commonly used as an opium substitute to treat pain or to treat mood disorders. 
• Also used to obtain a recreational high.
Effects 
• A low doses (1-5g) has stimulant effects causing increased alertness, stamina 
and euphoria.
• At high doses (5-15 grams) kratom acts on μ and κ opioid receptors causing 
increase euphoria, sedation, and analgesia.
• Effects begin 5-10 mins after use and last for 2-5 hours.
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Case resolution
• On day 5, multiple empty bags of “Maeng Da” 
tea were found in the patient’s home.
• Clonidine and hydroxyzine provided further 
improvement in his anxiety, tremor, and 
tachycardia. 
• Extubated on day 9.
• Once stable, induction therapy with 
buprenorphine was started and eventually 
discharged on day 18.
